The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis

Parasitology Research

Volumn 85, Issue 3, 1999, Pages 165-170

  Becker, Ingeborg ^a   Volkow, Patricia ^b   Velasco Castrejon, Oscar ^c   Salaiza Suazo, Norma ^a   Berzunza Cruz, Miriam ^d   Dominguez, Jose Sotero Delgado ^a   Morales Vargas, Armando ^a   Ruiz Remigio, Adriana ^a   Perez Montfort, Ruy ^e  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b SECRETARÍA DE SALUD   (Mexico)

^c Instituto Nacional de Diagnostico y Referencia Epidemiologicos   (Mexico)

^d UNIVERSIDAD AUTÓNOMA DE CAMPECHE   (Mexico)

^e INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; GAMMA INTERFERON; PENTAMIDINE;

ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DOSE RESPONSE; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; PROMASTIGOTE; RELAPSE; SKIN LEISHMANIASIS; TREATMENT INDICATION;

ADULT; ALLOPURINOL; ANIMALS; ANTIPROTOZOAL AGENTS; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DRUG SYNERGISM; HUMANS; INTERFERON-GAMMA, RECOMBINANT; LEISHMANIA MEXICANA; LEISHMANIASIS, DIFFUSE CUTANEOUS; MEXICO; PENTAMIDINE;

LEISHMANIA MEXICANA MEXICANA; PROTOZOA;

EID: 0032960092     PISSN: 00443255     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004360050529     Document Type: Article

References (15)

1. Badaro R, Johnson WD (1993) The role of interferon-γ in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 167: 13-17
2. Badaro R, Falcoff E, Badaro FS (1990) Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 322: 16-21
3. Becker I, Perez-Montfort R, Perez-Torres A, Vazquez-Arana S, Carrillo-Farga J, Salaiza N, Cruz B, Marquez-Monter H, Perez Tamayo R (1995) Inhibition of Leishmania growth but not of phagocytic functions of macrophages by 5-fluorouracil in vitro. Acta Protozool 34: 261-270
4. Berman JD (1988) Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 10: 560-586
5. Chance ML (1995) New developments in the chemotherapy of leishmaniasis. Ann Trop Med Parasitol 89: 37-43
6. Kadaro AY, Ghalib HW, Ali MS, Eltoum I, Ismail A, Gaafar A, Kemp M, Kordofani AAY, Reed SG, El-Hassan AM, Kharazmi A, Hag-Ali M, Mustafa MD (1993) Prevalence of cutaneous leishmaniasis along the Nile river north of Khartoum (Sudan) in the aftermath of an epidemic in 1985. Am J Trop Med Hyg 48: 44-49
7. Koff AB, Rosen T (1994) Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 31: 693-708
8. Liew FY (1989) Functional heterogeneity of CD4+ T cells in leishmaniasis. Immunol Today 10: 40-45
9. Murray HW (1990) Effect of continuous administration of interferon-γ in experimental visceral leishmaniasis. J Infect Dis 161: 992-994
10. Murray HW, Rubin BY, Rothermel CD (1983) Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes: evidence that interferon gamma is the activating lymphokine. J Clin Invest 72: 1506-1510
11. Murray HW, Berman JD, Wright SD (1988) Immunochemotherapy for intracellular Leishmania donovani infection: γ-interferon plus pentavalent antimony. J Infect Dis 157: 973-978
12. Nathan CF, Horowitz CR, De La Harpe J, Vadhan-Raj S, Sherwin SA, Oettgen HF, Krown SE (1985) Administration of interferon-γ to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci USA 82: 8686-8690
13. Olliaro PL, Bryceson ADM (1993) Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 9: 323-328
14. Velasco-Castrejón O (1994) Las leishmaniasis con especial referenda a México. Publicatión Técnica 7. INDRE, SSA, Mexico
15. World Health Organization (1997) Tropical disease research, progress 1995-96. Thirteenth program report, UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases; WHO, Geneva